MedTrace Logo

Transscleral Selective Laser Trabeculoplasty Project

NCT06833060 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-06-26

No results posted yet for this study

Summary

The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty.

Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors.

Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.

Conditions

  • Glaucoma,Open-Angle
  • Ocular Hypertension (OH)

Interventions

DEVICE

Selective Laser Trabeculoplasty

Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty

Sponsors & Collaborators

  • Quantel Medical

    collaborator INDUSTRY

  • Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)

    lead INDUSTRY

Principal Investigators

  • Robert J. CASSON, MBBS (Hons), M.Biostat, DPhil · Royal Adelaide Hospital - Harley Eye Clinic

  • Mario de La TORRE, Prof. Dr. med. · Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-19
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833060 on ClinicalTrials.gov